• RNA-powered multi-cancer multi-omics screening tests.
+ Gastric cancer screening test is first to be launched.+ Lung cancer screening test to be launched by end 2021.+ Tests for colorectal, liver, breast, pancreatic, and ovarian cancer to follow.
• Fast turn-around testing services for cancer treatment guidance and resistance prediction.
+ Launching APEX tissue and liquid biopsy testing services with 4-day turn-around.+ Testing for comprehensive genomic profiling, immunotherapy, haematology-oncology, and somatic mutations to follow.
+ Responded to pandemic with Fortitude COVID-19 RT-PCR diagnostic test and a range of comprehensive testing solutions.+ Tests for pulmonary hypertension, heart failure, and insulin resistance to follow.
Read more about our latest and key scientific publications here.
Mammography is extensively used for breast cancer screening but has high false-positive rates. This paper describes the discovery, development, and validation of a serum 6-miRNA panel to discriminate between malignant and benign breast lesions among women with abnormal mammograms.
Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.